Results 111 to 120 of about 49,828 (259)

Secular Trend in Glycaemic Management in Type 2 Diabetes Patients With and Without Cirrhosis Between 2000 and 2023: A Territory‐Wide Cohort Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In this territory‐wide cohort study, improving glycemic control can be observed regardless of cirrhosis status. Oral antidiabetic medication was more often used in the non‐cirrhosis group, and insulin was preferred in patients with decompensated cirrhosis, who exhibited an increasing incidence of hypoglycemia over the years and need individualized ...
Mary Yue Wang, Sherlot Juan Song, Nana Peng, Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong, Jimmy Che‐To Lai, Terry Cheuk‐Fung Yip   +6 more
wiley   +1 more source

Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metformin

, 2016
Xiaomei Peng, Dingfeng Jiang, Dongju Liu, Oralee J Varnado, Jay P Bae Eli Lilly and Company, Global Patient Outcomes and Real World Evidence, Indianapolis, IN, USA Background: Metformin is an oral antidiabetic drug (OAD) widely used as first-line ...
Peng X, Varnado OJ, Bae JP, Jiang D, Liu D   +4 more
core  

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

The multiple actions of dipeptidyl peptidase 4 (DPP-4) and its pharmacological inhibition on bone metabolism: a review

Diabetology & Metabolic Syndrome
Background Dipeptidyl peptidase 4 (DPP-4) plays a crucial role in breaking down various substrates. It also has effects on the insulin signaling pathway, contributing to insulin resistance, and involvement in inflammatory processes like obesity and type ...
L. M. Pechmann, F. I. Pinheiro, V. F. C. Andrade, C. A. Moreira   +3 more
doaj   +1 more source

Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats

, 2016
Rajesh Kumar Suman,1 Ipseeta Ray Mohanty,1 Ujwala Maheshwari,2 Manjusha K Borde,1 YA Deshmukh1 1Department of Pharmacology, 2Department of Pathology, MGM Medical College, Kamothe, Navi Mumbai, India Background: Mangiferin (MNG) is known to possess ...
Borde MK, Maheshwari U, Suman RK, Mohanty IR, Deshmukh YA   +4 more
core  

Changes in gastrointestinal motility and gut hormone secretion after Roux‐en‐Y gastric bypass and sleeve gastrectomy for individuals with severe obesity

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary Background Bariatric surgery is very effective in long‐term weight management. The present study was undertaken to investigate the short‐term effects of sleeve gastrectomy (SG) and of Roux‐en‐Y gastric bypass (RYGB) on (a) gastrointestinal (GI) motility, that is gastric emptying and oro‐cecal transit time and (b) secretion of regulatory gut ...
Jennifer A. Wilbrink, Mark van Avesaat, Simon W. Nienhuijs, Arnold Stronkhorst, Ad A. M. Masclee   +4 more
wiley   +1 more source

Evaluation of a secondary care multidisciplinary clinic for adults with early‐onset type 2 diabetes at high risk in Leicester, Leicestershire and Rutland

Diabetic Medicine, EarlyView.
Abstract Background Clinical services for adults with early‐onset type 2 diabetes (EOT2D) are in urgent need of improvement. Methods We evaluated a multi‐disciplinary clinic for individuals with EOT2D at high risk (HbA1c >9%/triglyceride >20 mmol/L), providing 2–3 flexibly arranged consultations per individual between March 2024 and September 2025 ...
Jonathan Goldney, Malak Hamza, Priscilla Sarkar, Harriet Morgan, Nicole Green, James Ridgeway, Victoria Alabraba, Laura Willcocks, Krupali Chandracant, Kashmala Javed, Rhys O'Callaghan, Finley Turner, Samuel Seidu, Claire L. Meek, Melanie J. Davies   +14 more
wiley   +1 more source

A retrospective sub‐study of perioperative glycaemia and insulin treatment for hospital inpatients at a quaternary centre from the specialist treatment of inpatients: Caring for diabetes in surgery trial (STOIC‐D Surgery)

Diabetic Medicine, EarlyView.
Abstract Aims Surgical inpatients experience variable glycaemia, with hyper and hypoglycaemia, contributing towards increased morbidity and mortality. Understanding of mechanisms for glycaemic variability and clinician responses remains limited. We aimed to describe patterns of glycaemia in the immediate perioperative period and its drivers, including ...
Florence Ho, Mervyn Kyi, Spiros Fourlanos, Peter G. Colman, Leon J. Worth, Rahul D. Barmanray   +5 more
wiley   +1 more source

Perioperative glycaemic profiles in Aboriginal and Torres Strait Islander people with diabetes mellitus

Diabetic Medicine, EarlyView.
This large multicentre retrospective cohort study in Australia revealed that despite being younger and having greater preoperative comorbidity and higher HbA1c levels, Aboriginal and Torres Strait Islander adults with diabetes mellitus demonstrate higher rates of perioperative hypoglycaemia, but otherwise comparable markers of glycaemic variability and
Katerina Flabouris, Odette R. Pearson, Kim Morey, Suzanne M. Edwards, David R. Jesudason, Chinmay S. Marathe   +5 more
wiley   +1 more source

Simplified Switching to Once‐Weekly Insulin Icodec Without an Initial One‐Time Additional Dose Versus Once‐Daily Insulin Glargine U100 in Basal Insulin‐Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims ONWARDS 10 assessed switching from daily basal insulins to once‐weekly insulin icodec without a one‐time additional dose at first injection. Materials and Methods In this treat‐to‐target, open‐label, 26‐week, phase 3b trial, adults with basal‐insulin‐treated type 2 diabetes (T2D) with glycated haemoglobin [HbA1c] 7.0%–10.0% were ...
Julio Rosenstock, Chantal Mathieu, Joshua Buron Feinberg, Priyanka Rao, Cathrine Scavenius, Alice Y. Y. Cheng   +5 more
wiley   +1 more source